Novo Nordisk has picked second RNA drug candidate for USD 358m collaboration

Novo Nordisk and US-based Dicerna, which in 2019 announced their million-dollar partnership to the develop potential RNA drugs, have chosen their second candidate. According to the Danish pharmaceutical company, the choice was made during the first half of the year.

BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

Published: 15.10.21 at 13:02

The multi-million-dollar collaboration between Novo Nordisk and US-based Dicerna, dealing with the development of new potential RNA drugs, has seen its second candidate, the former tells MedWatch.

According to the pharmaceutical companies, the selection occured in the first half of the year, meaning that so far, the partnership, which was announced in 2019, has resulted in two preclinical candidates for futher developement. Both are within cardiometabolic diseases, which is all Novo Nordisk is prepared to say.

Already a subscriber? Log in.

Read the whole article

Get 14 days free access.
No credit card required.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

"Real world" patient data documents the long-term effects of ALK vaccines

Data from ALK's React study, which is a retrospective real-world evidence study including more than 92,000 patients with respiratory allergies, have just been published in the journal The Lancet Regional Health – Europe. | Foto: ALK / PR

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.